GSKVX000000034798 (GSK)

GSKVX000000034798 is an mRNA-based vaccine candidate developed by GSK for the prevention of seasonal influenza. It is one of several mRNA constructs being evaluated as part of a multivalent seasonal influenza vaccine program. The vaccine utilizes messenger RNA technology to encode for specific influenza viral antigens, such as hemagglutinin, which are then expressed by the recipient's cells to induce a protective immune response. As of early 2025, it is in Phase 2a clinical development (e.g., trial 2025-522278-35-00) to evaluate its safety and immunogenicity in adults compared to standard inactivated influenza vaccines.